BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 6, 2024 to report its second quarter 2024 financial results and provide a corporate update. Also today, Rhythm announced that David Meeker, M.D., Chair, President and Ch ...

Heart rate and blood pressure monitoring: In Europe, heart rate and blood pressure should be monitored as part of standard clinical practice at each medical visit (at least every 6 months) for patients treated with setmelanotide. Other types of obesity not related to POMC, PCSK1 or LEPR deficiency, or BBS, including obesity associated with other genetic syndromes and general (polygenic) obesity. USE IN SPECIFIC POPULATIONS Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) ha ...

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization for IMCIVREE® (setmelanotide) include children between 2 and younger than 6 years ...

BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on June 6, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement equity grants covering an aggregate of 56,080 shares of its common stock to ten new employees, consisting of inducement stock options ...

Corporate Contact: David Connolly Head of Investor Relations and Corporate Communications Rhythm Pharmaceuticals, Inc. 857-264-4280 dconnolly@rhythmtx.com Media Contact: Adam Daley Berry & Company Public Relations 212-253-8881 adaley@berrypr.com Please see the full Prescribing Information for additional Important Safety Information. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release ...

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the presentation of the first patient and caregiver reported experiences from qualitative interviews following the completion of a Phase 2 trial that evaluated treatment with setmelanotide in hypothalamic obesity (HO). These results were among six Rhy ...

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m. The fireside chat will be webcasted and available unde ...

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m. The fireside chat will be webcasted and available unde ...

"BBS is a debilitating rare disease that severely affects quality of life of patients and their families," said Philip Beales, M.D., UCL Great Ormond Street Institute of Child Health. "Hyperphagia – the feeling of extreme hunger that stays with patients all the time – leads to early-onset, life-long, severe obesity that affects many aspects of daily living. Until now there have been no licensed treatments for obesity and hyperphagia caused by BBS." The final NICE recommendation is aligned to the European Ma ...

Rhythm Pharmaceuticals, Inc (NASDAQ:RYTM) Q1 2024 Results Conference Call May 7, 2024 8:00 AM ET Company Participants David Connolly - Executive Director, IR and Corporate Communications David Meeker - Chairman, President, and CEO Jennifer Lee - Executive Vice President, Head of North America Yann Mazabraud - Executive Vice President, Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Derek Archila - Wells Fargo Jeff Hung - Morgan Stanley Dae Gon Ha - Stifel Phil Nadea ...